{"disease":{"id":"acute-hae-attacks","name":"acute hae attacks"},"drugs":{"marketed":[{"drug_id":"ecallantide","indication_name":"Acute HAE Attacks","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Kalbitor","generic_name":"ECALLANTIDE","company_name":"Dyax Corp.","drug_phase":"marketed","molecular_target":"Plasma kallikrein","drug_class":"Plasma Kallikrein Inhibitor [EPC]","quality_score":62,"revenue":null,"mechanism":"Kalbitor works by blocking the plasma kallikrein enzyme, which is involved in the production of bradykinin, a key mediator of HAE symptoms."},{"drug_id":"icatibant-acetate","indication_name":"Acute HAE Attacks","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ICATIBANT ACETATE","company_name":"","drug_phase":"marketed","molecular_target":"bradykinin B2 receptor","drug_class":"","quality_score":50,"revenue":null,"mechanism":"Icatibant blocks bradykinin from binding to the B2 receptor, reducing HAE symptoms."}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05300997","title":"Translational Immunodiagnostics in Stroke (TrImS)","phase":"","overall_status":"RECRUITING","enrollment_count":650,"lead_sponsor_name":"The University of Hong Kong","has_results":false}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}